Acclarent, Inc. announced today the U.S. availability of the Relieva® Spin Balloon Sinuplasty System with the M-110C Sinus Guide Catheter Tip designed to access small and tight sinus anatomy in children and adults. This innovation represents a new addition to Acclarent’s Balloon Sinuplasty portfolio, which physicians use to treat children who suffer from chronic maxillary sinusitis.
Balloon Sinuplasty Technology is a safe and minimally invasive system that widens the sinus openings of patients suffering from chronic sinusitis. This technology, used by ear, nose and throat (ENT) surgeons to treat patients with chronic sinusitis, has an excellent safety profile and is an effective treatment for blocked sinuses.
Sinusitis is one of the most common chronic health problems in the U.S., with 18 million office visits per year for chronic sinusitis. Patients with chronic rhinosinusitis typically suffer from a combination of headaches, congestion, facial pain/pressure, and other symptoms impacting their physical, functional, and emotional quality of life. While chronic sinusitis is typically treated first with medication, at least 20 percent of patients do not respond adequately to such treatment. For children suffering from this condition, it can result is considerable loss of school time and accumulation of medical expenses.
“As the leader in Balloon Sinuplasty technology, Acclarent is pleased to offer the Relieva® Spin Balloon Sinuplasty System for children who suffer from chronic maxillary sinusitis,†said Dr. Howard Levine, otolaryngologist and Acclarent Vice President of Clinical and Medical Affairs. “Our Balloon technology has been used in over 300,000 adults and children who suffer from chronic sinusitis and this launch continues to support Acclarent’s mission to provide sinus relief to children as well.â€